Author: Zacks Small Cap Research

1333435363745350 / 450 POSTS
By John Vandermosten, CFANASDAQ:CRMEFor its fourth quarter and full year, Cardiome Pharma Corp (NASDAQ:CRME) reported revenues of $7.0 million and $24.0 million respectively, a (0.3%) and (5.1%) decline.  Fourth quarter net loss was ($8.3) million or ...
By Brian Marckx, CFANASDAQ:CTSOCytoSorbents (NASDAQ:CTSO) reported financial results for their fourth quarter ending December 31st and provided a business update.  Product sales continue their regular and rapid climb upward, setting another record an ...
By David Bautz, PhDNASDAQ:ARLZBusiness UpdateContinued Growth in Zontivity®Aralez (NASDAQ:ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary car ...
By David Bautz, PhDNASDAQ:OPNTBusiness UpdateOpioid Crisis Continues to WorsenA new report from the Centers for Disease Control (CDC) shows that emergency department visits for opioid overdoses rose 30% in the U.S. from July 2016 to September 2017. T ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. The company’s lead compounds include: VK5211, which is being developed fo ...
OTC: HSSHFIntroduced in 2009, Bitcoin was the first decentralized digital currency. One Bitcoin was worth roughly $0.003 in early 2010, according to Coinmarketcap.com data. By September of 2017, the Bitcoin / dollar exchange rate had climbed to over ...
By David Bautz, PhDNASDAQ:MTPBusiness UpdateSet to Initiate Clinical Trial of MTX110 in DIPGOn January 16, 2018, Midatech Pharma Plc (NASDAQ:MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) a ...
By Brian Marckx, CFANYSE:VNRXVolitionRx (NYSE:VNRX) reported Q4 results and provided a business update.  Relative to the financials, results continue to come in well within our expectations with Q4 operating expenses and EPS coming in at $4.2M and ($ ...
By Brian Marckx, CFAOTC:SMLRSemler (OTC:SMLR) reported financial results for their fourth quarter and full year ending December 31st.  Results were, again, extraordinarily strong, including revenue which set another new record high, beating the prio ...
By John Vandermosten, CFA NASDAQ:RXIIINITIATING COVERAGEWe are initiating coverage of RXi Pharmaceuticals Corp (NASDAQ:RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both thro ...
1333435363745350 / 450 POSTS